Clinical Trial Finder

Phase 1a

Inclusion Criteria:

1. Healthy female participants of non-childbearing potential and/or male participants between the ages of 18 and 55 years inclusive (ages 18 and 45 years for Part C). 2. BMI of 18 to 32 kg/m2; and a total body weight > 50 kg (110 lbs). 3. Evidence of a personally signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study. 4. Participants who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. 5. Nonsterile male participants must be willing to use a highly effective method of birth control and refrain from sperm donation for the duration of the study and for 90 days after the last dose of study drug. Phase 1b: Inclusion Criteria. 1. Female or male participants between the ages of 18 to 75 years of age. 2. AD Cohort E1: 1. Chronic AD diagnosed by the Eichenfield revised criteria of Hannifin and Rajka that has been present for at least 1 year before the Screening Visit. 2. Prior to baseline assessment, participants with AD must have used only nonmedicated topical emollients twice daily for at least 7 days, without any active ingredients or additives that could impact AD treatment (such as hyaluronic acid, urea, ceramide, or filaggrin degradation products). Participant's response to treatment must have remained inadequate at baseline. Additionally, the participant must be willing and able to adhere to standardized background topical therapy as outlined in the protocol throughout the remainder of the study. 3. PN Cohort E2: 1. Diagnosed as PN by a dermatologist for at least 3 months before the Screening Visit with prurigo lesions on upper limbs with or without lesions on the trunk or lower limbs. 2. Minimum of 20 PN lesions in total on either of the following: both legs, both arms, and/or the trunk at the Screening Visit and on Day 1. General

Inclusion Criteria:

1. Must agree to avoid prolonged exposure to the sun and not to use tanning booths, sun lamps, or other ultraviolet light sources during the study.

Exclusion Criteria:

1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). 2. Any condition possibly affecting drug absorption (eg, gastrectomy or cholecystectomy). 3. Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of investigational product, whichever is longer. 4. 12-lead ECG demonstrating QTcF > 450 milliseconds. 5. Clinically significant abnormality on chest radiograph performed at screening or within 3 months of screening date. 6. History of tuberculosis or active or latent or inadequately treated infection, positive IGRA tests. 7. Herbal supplements (including St. John's Wort) and hormone replacement therapy must be discontinued 14 days prior to the first dose of study medication. 8. Vaccination with live virus, attenuated live virus, or any live viral components within the 6 weeks prior to the first dose of study drug or is to receive these vaccines at any time during treatment or within 8 weeks following completion of study treatment. Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Arms

Experimental: Phase 1a Part A (Single Ascending Dose)

Phase 1a Part A is designed to assess the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic profile of BGB-45035 following single-ascending doses (SAD) in healthy participants.

Experimental: Phase 1a Part B (Multiple Ascending Dose)

Phase 1a Part B is designed to assess safety, tolerability, PK, and pharmacodynamic profile after repeated dosing of BGB-45035 in healthy participants.

Experimental: Phase 1a Part C (Chinese Substudy)

Phase 1a Part C is designed to assess safety, tolerability, PK, and pharmacodynamic profile after repeated dosing of BGB-45035 in healthy Chinese participants.

Experimental: Phase 1a Part D (Food Effect)

Phase 1a Part D is designed to assess the effect of food on BGB-45035 exposure.

Experimental: Phase 1b Part E (AD Cohort E1)

Phase 1b AD Cohort E1 is designed to assess the safety, tolerability, and efficacy of a selected dose of BGB-45035 in participants with moderate to severe AD.

Experimental: Phase 1b Part E (PN Cohort E2)

Phase 1b PN Cohort E2 is designed to assess the safety, tolerability, and efficacy of a targeted dose of BGB-45035 in participants with moderate to severe PN.

Interventions

Drug: - BGB-45035

Administered orally

Drug: - Placebo

Administered orally